|
|
 |
 |
| |
 Printable version |
Standards, Options and Recommendations (SOR) for the use of appetite stimulants in oncology |
Bulletin du Cancer. Volume 87, Number 4, 315-28, Avril 2000, Standards, Options et Recommandations
|
 Résumé
|
Author(s) : Jean-Claude Desport, Marie-Pierre Blanc-Vincent, Guillaume Gory-Delabaere, Patrick Bachmann, Jacqueline Béal, Robert Benamouzig, Virginie Colomb, David Kere, Jean-Claude Melchior, Gérard Nitenberg, Bruno Raynard, Stéphane Schneider, Pierre Senesse |
Summary : Context. The “Standards, Options and Recommendations” (SOR) project, started in 1993, is a collaboration between the Federation of the French Cancer Centres (FNCLCC), the 20 French Cancer Centres and specialists from French Public Universities, General Hospitals and Private Clinics. The main objective is the development of clinical practice guidelines to improve the quality of health care and outcome for cancer patients. The methodology is based on literature review and critical appraisal by a multidisciplinary group of experts, with feedback from specialists in cancer care delivery. Objectives. To develop clinical practice guidelines according to the definitions of the Standards, Options and Recommendations project for the use of appetite stimulants in oncology. Methods. Data were identified by searching Medline® and the personal reference lists of members of the expert groups. Once the guidelines were defined, the document was submitted for review to 55 independent reviewers, and to the medical committees of the 20 French Cancer Centres. Results. The main recommendations for the use of appetite stimulants in oncology are: 1) Corticosteroids and the synthetic progestogens (megestrol acetate and medroxyprogesterone acetate) are appetite stimulants. 2) They can be useful in managing anorexia and weight loss in cancer patients, especially in the palliative setting, despite the potential side-effects of these agents. 3) The most effective way of using these drugs is not known. Inclusion in clinical trials is recommended. 4) Cyproheptadine, metoclopramide, nandrolone and pentoxifylline should not be used outside prospective clinical trials. 5) Hydrazine sulfate should not be used. |
Keywords : appetite, anorexia, cachexia, appetite stimulants, guidelines, neoplasms, cancer. |
|
